Safety and immunogenicity of INO-4800 DNA vaccine against SARS-CoV-2: a preliminary report of a randomized, blinded, placebo-controlled, Phase 2 clinical trial in adults at high risk of viral exposure
Mammen P. Mammen Jr., Pablo Tebas, Joseph Agnes, Mary Giffear, Kimberly A. Kraynyak, Elliott Blackwood, Dinah Amante, Emma L. Reuschel, Mansi Purwar, Aaron Christensen-Quick, Nieman Liu, Viviane M. Andrade, Julie Carter, Gabriella Garufi, Malissa C. Diehl, Albert Sylvester, Matthew P. Morrow, Patrick Pezzoli, Abhijeet J. Kulkarni, Faraz I. Zaidi, Drew Frase, Kevin Liaw, Hedieh Badie, Keiko O. Simon, Trevor R.F. Smith, Stephanie Ramos, Robert Spitz, Robert J. Juba, Jessica Lee, Michael Dallas, Ami Shah Brown, Jacqueline E. Shea, J. Joseph Kim, David B. Weiner, Kate E. Broderick, Jean D. Boyer, Laurent M. Humeau
medRxiv 2021.05.07.21256652; doi: https://doi.org/10.1101/2021.05.07.21256652